Paradigm Capital Management LLC NV Has $2.28 Million Position in Pfizer Inc. (NYSE:PFE)

Paradigm Capital Management LLC NV cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 86,078 shares of the biopharmaceutical company’s stock after selling 6,564 shares during the period. Pfizer accounts for about 2.1% of Paradigm Capital Management LLC NV’s investment portfolio, making the stock its 12th biggest holding. Paradigm Capital Management LLC NV’s holdings in Pfizer were worth $2,284,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of PFE. Parsons Capital Management Inc. RI lifted its position in shares of Pfizer by 118.7% in the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after buying an additional 159,984 shares during the last quarter. Mcdonald Partners LLC increased its stake in shares of Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock worth $2,926,000 after purchasing an additional 9,963 shares during the period. Merit Financial Group LLC increased its stake in shares of Pfizer by 60.8% during the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock worth $3,395,000 after purchasing an additional 48,397 shares during the period. Bank of Jackson Hole Trust bought a new position in shares of Pfizer during the fourth quarter worth approximately $264,000. Finally, Amplius Wealth Advisors LLC increased its stake in shares of Pfizer by 80.7% during the fourth quarter. Amplius Wealth Advisors LLC now owns 46,823 shares of the biopharmaceutical company’s stock worth $1,242,000 after purchasing an additional 20,911 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent research reports. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective on the stock. Finally, UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Stock Performance

Shares of PFE opened at $22.86 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business’s 50 day moving average price is $23.89 and its 200-day moving average price is $25.46. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The stock has a market cap of $129.97 billion, a P/E ratio of 16.21, a P/E/G ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.82 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.52%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.